The Importance of Proactively Addressing and De-labeling Antibiotic Allergy (AAN)

Price: FREE for members and non-members

Session recorded on January 29, 2024
Speaker: Kimberly Blumenthal, MD, MSC

With the rise of drug-resistant organisms, proactive evaluation and delabeling of inaccurate antibiotic allergies is a key component of antibiotics stewardship and quality improvement. Unverified penicillin allergies can have adverse consequences for public health and individual health. The goal of proactive penicillin allergy evaluations is to remove the label if the allergy is found to be untrue.

Viewers can earn credit by completing the post-test questions.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

At the conclusion of this activty, learners should be able to:
1.    Describe the importance of proactive penicillin allergy evaluations and delabeling.
2.    Explain how to perform a penicillin allergy evaluation. 
3.    Identify the populations most at risk of an unverified penicillin allergy label.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
01/29/2024
Course expires: 
12/31/2024
Rating: 
0

All identified relevant financial relationships with ineligible companies have been mitigated.

Kimberly Blumenthal, MD, MSC, Speaker

Researcher: ThermoFischer
Royalties: UpToDate
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.